Advanced search
Publication Cover
Journal of Addictive Diseases Volume 38, 2020 - Issue 4
Submit an article Journal homepage
413
Views
26
CrossRef citations to date
0
Altmetric
Original Articles

Prevalence and characteristics of self-reported kratom use in a representative US general population sample

Jordan R. Covveya Division of Pharmaceutical, Administrative and Social Sciences, School of Pharmacy, Duquesne University, Pittsburgh, PA, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-2913-2042View further author information
, PharmD, PhD, BCPSORCID Icon,
Samantha M. Vogelb Pharmacotherapy Division, College of Pharmacy, The University of Texas at Austin, Austin, TX, USA;c Dell Medical School, UT Health Austin, Austin, TX, USAView further author information
, PharmD, BCPP,
Alyssa M. Peckhamd Department of Pharmacy, Massachusetts General Hospital, Boston, MA, USA;e Department of Pharmacy and Health Systems Sciences, School of Pharmacy, Bouvé College of Health Sciences, Northeastern University, Boston, MA, USAView further author information
, PharmD, BCPP &
Kirk E. Evoyb Pharmacotherapy Division, College of Pharmacy, The University of Texas at Austin, Austin, TX, USA;f Southeast Clinic, University Health System, San Antonio, TX, USA;g Long School of Medicine, UT Health San Antonio, San Antonio, TX, USAORCID Iconhttps://orcid.org/0000-0003-0913-7145View further author information
, PharmD, BCACP, BC-ADM, CTTSORCID Icon
Pages 506-513 | Published online: 12 Jul 2020

Citations (26)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (6)

Nicholas A Deebel, Kyle Scarberry, Collette A O’Connor, Rahul Dutta, Ethan Matz, Colleen A Hanlon & Ryan P Terlecki. (2023) Investigating the Impact of Kratom (Mitragyna speciosa) Use Upon Male Sexual Health. Research and Reports in Urology 15, pages 69-76.
Read now
C. R. LoParco, R. A. Yockey, V. K. Sekhon, S. Olsson, R. Galindo, R. Balasundaram, T. Agwuncha & M. E. Rossheim. (2023) Kratom Retail Availability in Fort Worth, Texas. Journal of Psychoactive Drugs 0:0, pages 1-6.
Read now
Oliver Grundmann, Charles A. Veltri, Diana Morcos, David Knightes$suffix/text()$suffix/text(), Kirsten E. Smith & Jeffery M. Rogers. (2022) How essential is kratom availability and use during COVID-19? Use pattern analysis based on survey and social media data. Substance Abuse 43:1, pages 865-877.
Read now
Kirsten E. Smith, Jeffrey M. Rogers & Justin C. Strickland. (2022) Associations of Lifetime Nonmedical Opioid, Methamphetamine, and Kratom Use within a Nationally Representative US Sample. Journal of Psychoactive Drugs 54:5, pages 429-439.
Read now
Cornel Stanciu, Saeed Ahmed, Samantha Gnanasegaram, Stephen Gibson, Thomas Penders, Oliver Grundmann & Christopher McCurdy. (2022) Kratom as an opioid alternative: harm, or harm reduction? A systematic review of literature. The American Journal of Drug and Alcohol Abuse 48:5, pages 509-528.
Read now
Oliver Grundmann, Charles A. Veltri, Diana Morcos, David Knightes$suffix/text()$suffix/text(), Kirsten E. Smith, Darshan Singh, Ornella Corazza, Eduardo Cinosi, Giovanni Martinotti, Zach Walsh & Marc T. Swogger. (2022) Exploring the self-reported motivations of kratom (Mitragyna speciosa Korth.) use: a cross-sectional investigation. The American Journal of Drug and Alcohol Abuse 48:4, pages 433-444.
Read now

Articles from other publishers (20)

Maximilian Gahr. (2022) Kratom (Mitragyna speciosa): eine psychoaktive Pflanze mit Chancen und Risiken. Fortschritte der Neurologie · Psychiatrie 91:11, pages 455-465.
Crossref
Molly A. Bowdring, Eric C. Leas, Monika Vishwakarma, Nina C. Schleicher, Judith J. Prochaska & Lisa Henriksen. (2023) Kratom availability in California vape shops. Preventive Medicine Reports 35, pages 102380.
Crossref
Daniel J. Farkas, Saadet Inan, Laila N. Heydari, Clare T. Johnson, Pingwei Zhao, Heather B. Bradshaw, Sara Jane Ward & Scott M. Rawls. (2023) Cannabinoid mechanisms contribute to the therapeutic efficacy of the kratom alkaloid mitragynine against neuropathic, but not inflammatory pain. Life Sciences 328, pages 121878.
Crossref
Daniel J. Farkas, Ziva D. Cooper, Laila N. HeydariAmanda C. HughesScott M. RawlsSara Jane Ward. (2023) Kratom Alkaloids, Cannabinoids, and Chronic Pain: Basis of Potential Utility and Role in Therapy. Cannabis and Cannabinoid Research.
Crossref
Oliver Grundmann, Robert G. Hendrickson & Michael I. Greenberg. (2023) Kratom: History, pharmacology, current user trends, adverse health effects and potential benefits. Disease-a-Month 69:6, pages 101442.
Crossref
Elisabeth Prevete, Kim Paula Colette Kuypers, Eef Lien Theunissen, Gianluca Esposito, Johannes Gerardus Ramaekers, Massimo Pasquini & Ornella Corazza. (2023) Clinical Implications of Kratom (Mitragyna speciosa) Use: a Literature Review. Current Addiction Reports 10:2, pages 317-334.
Crossref
Kirsten Elin Smith, Jeffrey M. Rogers & Jeffrey D. Feldman. (2023) Kratom’s Emergence and Persistence Within the US Polydrug Epidemic. Current Addiction Reports 10:2, pages 262-271.
Crossref
Katherine Hill, Stephen Gibson, Oliver Grundmann, Kirsten E. Smith, Jonathan Ballard & Corneliu N. Stanciu. (2023) Evaluating health information provided to kratom consumers by good manufacturing practice-qualified vendors. Substance Abuse Treatment, Prevention, and Policy 18:1.
Crossref
Kirk E Evoy, Shelby Humpert, Sorina Torrez, Haneen Hussein & Jordan R Covvey. (2023) Quetiapine and olanzapine misuse prevalence in a US general population sample. Mental Health Clinician 13:2, pages 25-35.
Crossref
Jack E. Henningfield, Joseph V. Rodricks, Aaron M. Magnuson & Marilyn A. Huestis. (2022) Respiratory effects of oral mitragynine and oxycodone in a rodent model. Psychopharmacology 239:12, pages 3793-3804.
Crossref
David Adzrago, Elizabeth O. Obekpa, Tiffany A. Suragh, Evit R. John, Paul G. Yeh, Kathryn R. Gallardo & J. Michael Wilkerson. (2022) Kratom use categories and their associations with co-occurring substance use and mental health disorder symptoms during the COVID-19 pandemic. Drug and Alcohol Dependence 239, pages 109605.
Crossref
Samantha Hughes, David van de Klashorst, Charles A. Veltri & Oliver Grundmann. (2022) Acute, Sublethal, and Developmental Toxicity of Kratom (Mitragyna speciosa Korth.) Leaf Preparations on Caenorhabditis elegans as an Invertebrate Model for Human Exposure. International Journal of Environmental Research and Public Health 19:10, pages 6294.
Crossref
Marc T. Swogger, Kirsten E. Smith, Albert Garcia-Romeu, Oliver Grundmann, Charles A. Veltri, Jack E. Henningfield & Lorna Y. Busch. (2022) Understanding Kratom Use: A Guide for Healthcare Providers. Frontiers in Pharmacology 13.
Crossref
Kirsten E. Smith, Jeffrey M. Rogers, Kelly E. Dunn, Oliver Grundmann, Christopher R. McCurdy, Destiny Schriefer & David H. Epstein. (2022) Searching for a Signal: Self-Reported Kratom Dose-Effect Relationships Among a Sample of US Adults With Regular Kratom Use Histories. Frontiers in Pharmacology 13.
Crossref
Jack E. Henningfield, Daniel W. Wang & Marilyn A. Huestis. (2022) Kratom Abuse Potential 2021: An Updated Eight Factor Analysis. Frontiers in Pharmacology 12.
Crossref
Jeffrey M Rogers, Kirsten E Smith, Destiny Schriefer & David H Epstein. (2022) For Better or Worse: Self-reported Changes in Kratom and Other Substance Use as a Result of the COVID-19 Pandemic. Substance Abuse: Research and Treatment 16, pages 117822182211239.
Crossref
Catherine W Striley, Carolin C Hoeflich, Andrew T Viegas, Lindsey A Berkowitz, Emily G Matthews, Leyla P Akin, Chidinma Iheanyi-Okeahialam, Urmeen Mansoor & Christopher R McCurdy. (2022) Health Effects Associated With Kratom ( Mitragyna speciosa ) and Polysubstance Use: A Narrative Review . Substance Abuse: Research and Treatment 16, pages 117822182210958.
Crossref
Jack E. Henningfield, Oliver Grundmann, Albert Garcia-Romeu & Marc T. Swogger. (2022) We Need Better Estimates of Kratom Use Prevalence. American Journal of Preventive Medicine 62:1, pages 132-133.
Crossref
Joseph J. Palamar. (2021) Past-Year Kratom Use in the U.S.: Estimates From a Nationally Representative Sample. American Journal of Preventive Medicine 61:2, pages 240-245.
Crossref
David Vearrier & Oliver Grundmann. (2021) Clinical Pharmacology, Toxicity, and Abuse Potential of Opioids. The Journal of Clinical Pharmacology 61:S2.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.